Historical Valuation
Stoke Therapeutics Inc (STOK) is now in the Overvalued zone, suggesting that its current forward PS ratio of 99.55 is considered Overvalued compared with the five-year average of -7.59. The fair price of Stoke Therapeutics Inc (STOK) is between 11.20 to 26.05 according to relative valuation methord. Compared to the current price of 33.68 USD , Stoke Therapeutics Inc is Overvalued By 29.28%.
Relative Value
Fair Zone
11.20-26.05
Current Price：33.68
29.28%
Overvalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Stoke Therapeutics Inc (STOK) has a current Price-to-Book (P/B) ratio of 5.53. Compared to its 3-year average P/B ratio of 2.58 , the current P/B ratio is approximately 113.88% higher. Relative to its 5-year average P/B ratio of 3.05, the current P/B ratio is about 81.27% higher. Stoke Therapeutics Inc (STOK) has a Forward Free Cash Flow (FCF) yield of approximately 2.97%. Compared to its 3-year average FCF yield of -15.25%, the current FCF yield is approximately -119.45% lower. Relative to its 5-year average FCF yield of -11.27% , the current FCF yield is about -126.32% lower.
P/B
Median3y
2.58
Median5y
3.05
FCF Yield
Median3y
-15.25
Median5y
-11.27
Competitors Valuation Multiple
AI Analysis for STOK
The average P/S ratio for STOK competitors is 101.67, providing a benchmark for relative valuation. Stoke Therapeutics Inc Corp (STOK.O) exhibits a P/S ratio of 99.55, which is -2.08% above the industry average. Given its robust revenue growth of 117.25%, this premium appears sustainable.
Performance Decomposition
AI Analysis for STOK
1Y
3Y
5Y
Market capitalization of STOK increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of STOK in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is STOK currently overvalued or undervalued?
Stoke Therapeutics Inc (STOK) is now in the Overvalued zone, suggesting that its current forward PS ratio of 99.55 is considered Overvalued compared with the five-year average of -7.59. The fair price of Stoke Therapeutics Inc (STOK) is between 11.20 to 26.05 according to relative valuation methord. Compared to the current price of 33.68 USD , Stoke Therapeutics Inc is Overvalued By 29.28% .
What is Stoke Therapeutics Inc (STOK) fair value?
STOK's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Stoke Therapeutics Inc (STOK) is between 11.20 to 26.05 according to relative valuation methord.
How does STOK's valuation metrics compare to the industry average?
The average P/S ratio for STOK's competitors is 101.67, providing a benchmark for relative valuation. Stoke Therapeutics Inc Corp (STOK) exhibits a P/S ratio of 99.55, which is -2.08% above the industry average. Given its robust revenue growth of 117.25%, this premium appears sustainable.
What is the current P/B ratio for Stoke Therapeutics Inc (STOK) as of Jan 09 2026?
As of Jan 09 2026, Stoke Therapeutics Inc (STOK) has a P/B ratio of 5.53. This indicates that the market values STOK at 5.53 times its book value.
What is the current FCF Yield for Stoke Therapeutics Inc (STOK) as of Jan 09 2026?
As of Jan 09 2026, Stoke Therapeutics Inc (STOK) has a FCF Yield of 2.97%. This means that for every dollar of Stoke Therapeutics Inc’s market capitalization, the company generates 2.97 cents in free cash flow.
What is the current Forward P/E ratio for Stoke Therapeutics Inc (STOK) as of Jan 09 2026?
As of Jan 09 2026, Stoke Therapeutics Inc (STOK) has a Forward P/E ratio of -9.98. This means the market is willing to pay $-9.98 for every dollar of Stoke Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Stoke Therapeutics Inc (STOK) as of Jan 09 2026?
As of Jan 09 2026, Stoke Therapeutics Inc (STOK) has a Forward P/S ratio of 99.55. This means the market is valuing STOK at $99.55 for every dollar of expected revenue over the next 12 months.